Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Karayama M, Inui N, Inoue Y, Yoshimura K, Mori K, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Suda T. Karayama M, et al. Among authors: kusagaya h. Cancer Immunol Immunother. 2022 Jan;71(1):203-217. doi: 10.1007/s00262-021-02979-4. Epub 2021 Jun 5. Cancer Immunol Immunother. 2022. PMID: 34091744 Free PMC article.
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Kusagaya H, Inui N, Karayama M, Nakamura Y, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K. Kusagaya H, et al. Lung Cancer. 2012 Sep;77(3):550-5. doi: 10.1016/j.lungcan.2012.05.106. Epub 2012 Jun 15. Lung Cancer. 2012. PMID: 22705118 Clinical Trial.
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T. Kusagaya H, et al. Lung Cancer. 2015 Dec;90(3):410-6. doi: 10.1016/j.lungcan.2015.11.009. Epub 2015 Nov 7. Lung Cancer. 2015. PMID: 26791800 Clinical Trial.
Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
Karayama M, Inui N, Kusagaya H, Suzuki S, Inoue Y, Enomoto N, Fujisawa T, Nakamura Y, Suda T. Karayama M, et al. Among authors: kusagaya h. Cancer Chemother Pharmacol. 2016 May;77(5):1011-8. doi: 10.1007/s00280-016-3017-7. Epub 2016 Mar 31. Cancer Chemother Pharmacol. 2016. PMID: 27034279
Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
Suzuki Y, Inui N, Karayama M, Imokawa S, Yamada T, Yokomura K, Asada K, Kusagaya H, Kaida Y, Matsuda H, Koshimizu N, Toyoshima M, Masuda M, Hayakawa H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Suda T. Suzuki Y, et al. Among authors: kusagaya h. Int J Chron Obstruct Pulmon Dis. 2019 Aug 21;14:1867-1877. doi: 10.2147/COPD.S214610. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 31686799 Free PMC article.
Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study.
Suzuki Y, Karayama M, Uto T, Fujii M, Matsui T, Asada K, Kusagaya H, Kato M, Matsuda H, Matsuura S, Toyoshima M, Mori K, Ito Y, Koyauchi T, Yasui H, Hozumi H, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T. Suzuki Y, et al. Among authors: kusagaya h. J Thorac Oncol. 2020 Aug;15(8):1317-1327. doi: 10.1016/j.jtho.2020.04.002. Epub 2020 Apr 11. J Thorac Oncol. 2020. PMID: 32289515 Free article.
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y, Yoshimura K, Nishimoto K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Asada K, Uto T, Fujii M, Matsui T, Matsuura S, Hashimoto D, Toyoshima M, Kusagaya H, Matsuda H, Inami N, Kaida Y, Niwa M, Ito Y, Sugimura H, Suda T. Inoue Y, et al. Among authors: kusagaya h. JAMA Netw Open. 2020 Sep 1;3(9):e2011818. doi: 10.1001/jamanetworkopen.2020.11818. JAMA Netw Open. 2020. PMID: 32955570 Free PMC article.
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
Miyashita K, Karayama M, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kono M, Matsui T, Niwa M, Koda K, Toyoshima M, Matsushima S, Matsuura S, Asada K, Fujii M, Kusagaya H, Matsuda H, Inui N, Suda T. Miyashita K, et al. Among authors: kusagaya h. BMC Pulm Med. 2021 Oct 2;21(1):309. doi: 10.1186/s12890-021-01681-6. BMC Pulm Med. 2021. PMID: 34600514 Free PMC article.
31 results